OKYO Pharma (OKYO) Total Debt (2023 - 2025)

OKYO Pharma (OKYO) reported Total Debt of $185795.0 for Q3 2025, up 10176.27% year-over-year from N/an in Q3 2024, and down 78.38% quarter-over-quarter from $859325.0 in Q1 2025.

OKYO Pharma (OKYO) Total Debt (2023 - 2025) Analysis & Trends

OKYO Pharma (OKYO) has 3 years of Total Debt data on file, last reported at $185795.0 in Q3 2025.

  • Total Debt for Q3 2025 came in at $185795.0, up 10176.27% year-over-year; the trailing twelve-month figure through Sep 2025 was $185795.0 (up 10176.27% YoY), and the FY2025 annual result was $859325.0, up 139.56% from the prior year.
  • Total Debt slipped to $185795.0 in Q3 2025 per OKYO's latest filing, from $859325.0 in the prior quarter.
  • Over five years, Total Debt peaked at $859325.0 in Q1 2025 and troughed at $1808.0 in Q3 2024.
  • A 3-year average of $384836.6 and a median of $358709.0 in 2024 frame the typical range for Total Debt.
  • The sharpest annual moves came in 2024 and 2025: Total Debt sank 99.65% in 2024, then soared 10176.27% in 2025.
  • A 3-year view of Total Debt shows it stood at $518546.0 in 2023, then slumped by 99.65% to $1808.0 in 2024, then soared by 10176.27% to $185795.0 in 2025.
  • Business Quant data shows OKYO's Total Debt at $185795.0 in Q3 2025, $859325.0 in Q1 2025, and $1808.0 in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 319.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 OKYO Pharma 240.90 Mn 236.68 Mn - 185,795.00

Historic Data

Download Data
DateValue
Sep 30, 2025 185,795.00
Mar 31, 2025 859,325.00
Sep 30, 2024 1,808.00
Mar 31, 2024 358,709.00
Sep 30, 2023 518,546.00